H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Argenx to $490 from $448 and keeps a Buy rating on the shares. The Cohort 1 data from the Phase 2 ARDA study showed empasiprubart’s improving grip strength in multifocal motor neuropathy patients, the analyst tells investors in a research note. The firm sees upside potential to numbers for the chronic inflammatory demyelinating polyneuropathy launch, which it expects is going to drive multiple expansion for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Unveils Promising Autoimmune Therapy Data
- argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
- Argenx price target raised to EUR 390 from EUR 375 at Barclays
- Argenx price target raised to $512 from $463 at Citi
- Argenx price target raised to $416 from $408 at Scotiabank